Audiologic and vestibular assessment in patients with β-thalassemia major receiving long-term transfusion therapy

Pediatric Blood and Cancer

Volumn 60, Issue 12, 2013, Pages 1963-1966

  Chao, Yu Hua ^a,b   Wu, Kang Hsi ^c,d   Lin, Ching Yu ^c   Tsai, Ming Hsui ^c,e   Peng, Ching Tien ^c,d,f   Wu, Han Ping ^g   Lin, Chia Der ^c,e  

^a CHUNG SHAN MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^c CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^d CHINA MEDICAL UNIVERSITY   (Taiwan)

^e CHINA MEDICAL UNIVERSITY   (Taiwan)

^f ASIA UNIVERSITY   (Taiwan)

^g BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

Author keywords

Chelation; Ototoxicity; Thalassemia; Transfusion

Indexed keywords

DEFERIPRONE; DEFEROXAMINE; FERRITIN;

ADOLESCENT; ADULT; ARTICLE; AUDIOLOGY; BLOOD TRANSFUSION; BRAIN STEM RESPONSE; CALORIC VESTIBULAR TEST; CHILD; CLINICAL ARTICLE; CLINICAL ASSESSMENT; FEMALE; FERRITIN BLOOD LEVEL; HEARING IMPAIRMENT; HUMAN; MALE; OTOACOUSTIC EMISSION; OTOSCOPY; PARESIS; PRIORITY JOURNAL; PURE TONE AUDIOMETRY; SCHOOL CHILD; THALASSEMIA MAJOR; TRANSIENT EVOKED OTOACOUSTIC EMISSION; TYMPANOMETRY; VESTIBULAR DISORDER; VESTIBULAR FUNCTION;

CHELATION; OTOTOXICITY; THALASSEMIA; TRANSFUSION;

ACOUSTIC IMPEDANCE TESTS; ADOLESCENT; ADULT; AUDIOMETRY, PURE-TONE; BETA-THALASSEMIA; BLOOD TRANSFUSION; CHELATING AGENTS; CHILD; DEFEROXAMINE; EVOKED POTENTIALS, AUDITORY, BRAIN STEM; FEMALE; HEARING LOSS; HUMANS; MALE; PYRIDONES; VESTIBULE, LABYRINTH; YOUNG ADULT;

EID: 84885755330     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24699     Document Type: Article

References (30)

1. Logothetis J, Constantoulakis M, Economidou J, et al. Thalassemia major (homozygous beta-thalassemia). A survey of 138 cases with emphasis on neurologic and muscular aspects. Neurology 1972; 22:294-304.
2. Smith RS. Iron excretion in thalassaemia major after administration of chelating agents. Br Med J 1962; 2:1577-1580.
3. Chen SH, Liang DC, Lin HC, et al. Auditory and visual toxicity during deferoxamine therapy in transfusion-dependent patients. J Pediatr Hematol Oncol 2005; 27:651-653.
4. Karimi M, Asadi-Pooya AA, Khademi B, et al. Evaluation of the incidence of sensorineural hearing loss in beta-thalassemia major patients under regular chelation therapy with desferrioxamine. Acta Haematol 2002; 108:79-83.
5. Chiodo AA, Alberti PW, Sher GD, et al. Desferrioxamine ototoxicity in an adult transfusion-dependent population. J Otolaryngol 1997; 26:116-122.
6. Kontzoglou G, Koussi A, Tsatra J, et al. Sensorineural hearing loss in children with thalassemia major in Northern Greece. Int J Pediatr Otorhinolaryngol 1996; 35:223-230.
7. Triantafyllou N, Fisfis M, Sideris G, et al. Neurophysiological and neuro-otological study of homozygous beta-thalassemia under long-term desferrioxamine (DFO) treatment. Acta Neurol Scand 1991; 83:306-308.
8. Cohen A, Martin M, Mizanin J, et al. Vision and hearing during deferoxamine therapy. J Pediatr 1990; 117:326-330.
9. Cases A, Kelly J, Sabater F, et al. Ocular and auditory toxicity in hemodialyzed patients receiving desferrioxamine. Nephron 1990; 56:19-23.
10. Wonke B, Hoffbrand AV, Aldouri M, et al. Reversal of desferrioxamine induced auditory neurotoxicity during treatment with Ca-DTPA. Arch Dis Child 1989; 64:77-82.
11. Porter JB, Jaswon MS, Huehns ER, et al. Desferrioxamine ototoxicity: Evaluation of risk factors in thalassaemic patients and guidelines for safe dosage. Br J Haematol 1989; 73:403-409.
12. Albera R, Pia F, Morra B, et al. Hearing loss and desferrioxamine in homozygous beta-thalassemia. Audiology 1988; 27:207-214.
13. Barratt PS, Toogood IR. Hearing loss attributed to desferrioxamine in patients with beta-thalassaemia major. Med J Aust 1987; 147:177-179.
14. Olivieri NF, Buncic JR, Chew E, et al. Visual and auditory neurotoxicity in patients receiving subcutaneous deferoxamine infusions. N Engl J Med 1986; 314:869-873.
15. De Virgiliis S, Argiolu F, Sanna G, et al. Auditory involvement in thalassemia major. Acta Haematol 1979; 61:209-215.
16. Peng CT, Chow KC, Chen JH, et al. Safety monitoring of cardiac and hepatic systems in beta-thalassemia patients with chelating treatment in Taiwan. Eur J Haematol 2003; 70:392-397.
17. Harrell RW. Pure tone evaluation. In: Katz J, editor. Handbook of clinical audiology, 5th edition. Philadelphia: Lippincott Williams & Wilkins; 2002. pp. 71-87.
18. Walker JJ, Cleveland LM, Davis JL, et al. Audiometry screening and interpretation. Am Fam Physician 2013; 87:41-47.
19. Jerger J. Clinical experience with impedance audiometry. Arch Otolaryngol 1970; 92:311-324.
20. Holtby I, Forster DP. Evaluation of pure tone audiometry and impedance screening in infant schoolchildren. J Epidemiol Commun H 1992; 46:21-25.
21. Korres S, Nikolopoulos T, Ferekidis E, et al. Otoacoustic emissions in universal hearing screening: Which day after birth should we examine the newborns? ORL J Otorhinolaryngol Relat Spec 2003; 65:199-201.
22. Proschel U, Eysholdt U. Specificity and sensitivity of transient click-evoked otoacoustic emissions (TEOAE). Laryngo-Rhino-Otologie 1995; 74:481-488.
23. Watson DR. A study of the effects of cochlear loss on the auditory brainstem response (ABR) specificity and false positive rate in retrocochlear assessment. Audiology 1999; 38:155-164.
24. Schmidt RJ, Sataloff RT, Newman J, et al. The sensitivity of auditory brainstem response testing for the diagnosis of acoustic neuromas. Arch Otolaryngol Head Neck Surgery 2001; 127:19-22.
25. Jongkees LB. Electronystagmography: Its use and usefulness. Ann Otol Rhinol Laryngol 1968; 77:733-739.
26. Zapala DA, Olsholt KF, Lundy LB. A comparison of water and air caloric responses and their ability to distinguish between patients with normal and impaired ears. Ear Hear 2008; 29:585-600.
27. Hall JW, Antonelli PJ. Assessment of peripheral and central auditory function. In: Bailey BJ, Johnson JT, Newlands SD, editors. Head & Neck Surgery-Otolaryngology, 4th edition. Philadelphia: Lippincott Williams & Wilkins; 2006. pp. 1928-1943.
28. Stadtman ER. Oxidation of free amino acids and amino acid residues in proteins by radiolysis and by metal-catalyzed reactions. Annu Rev Biochem 1993; 62:797-821.
29. Ryals B, Westbrook E, Schacht J. Morphological evidence of ototoxicity of the iron chelator deferoxamine. Hear Res 1997; 112:44-48.
30. Rosenfeld RM, Goldsmith AJ, Tetlus L, et al. Quality of life for children with otitis media. Arch Otolaryngol Head Neck Surg 1997; 123:1049-1054.